XYLID-P consists of a combination of Nimesulide and Paracetamol tablets. This medication helps to get relief from pain and inflammation. Nimesulide and Paracetamol Tablets are commonly used for patients suffering from ankylosing spondylitis, rheumatoid arthritis, and osteoarthritis. It’s also used in Fever, back pain, muscle pain, or pain in teeth or ears. It blocks certain chemical messengers because of why the patient feels relief from pain.
Precautions for Nimesulide and Paracetamol Tablets
Nimesulide and Paracetamol Tablets must be swallowed as a whole, without chewing. It is recommended to be taken with food. The patient should avoid taking alcohol while treatment for this medication. If the patient is pregnant, breastfeeds, or has any kidney problem then they should consult with the doctor before starting its treatment.
Side effects of Nimesulide and Paracetamol Tablets
Nimesulide and Paracetamol Tablets may cause some side effects which go away with time as the body adjusts itself, but if they don’t then let the doctor know about it.
Contact for Nimesulide and Paracetamol Tablets Manufacturing And Supply
Soigner Pharma is one of the top Pharma companies when it comes to quality product manufacturing. Our firm is ISO certified which provides quality pharma products at very nominal rates which fit in everybody’s pocket. We adhere to all the guidelines issued by WHO & GMP in order to make them compete with the global standards. Soigner Pharma is also a well-known Nimesulide and Paracetamol Tablets manufacturer and supplier in India. We have a diverse portfolio of quality pharma products. Our firm also offers PCD Pharma Franchise for Nimesulide and Paracetamol Tablets.
• ABSORPTION: – Rapidly absorbed following oral administration.
• METABOLISM: – Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).
• ROUTE OF ELIMINATION: – Renal (50%), fecal (29%)
• HALF-LIFE: -1.8–4.7 hours
• ABSORPTION: – Rapid and almost complete
• PROTEIN BINDING: -25%
• METABOLISM: – It primarily undergoes glucuronidation (45-55% of the dose) in which this process is facilitated by UGT1A1, UGT1A6, UGT1A9, UGT2B15 in the liver or UGT1A10 in the gut. 30-35% of the dose undergoes sulfation. This biotransformation is facilitated by SULT1A1, SULT1A3, SULT1A4, SULT1E1 and SULT2A1. A small percentage of paracetamol is oxidized by CYP2E1 to form N-acetyl-p-benzo-quinone imine (NAPQI), a toxic metabolite which is then conjugated to glutathione and excreted renally. Studies suggest that CYP3A4 and CYP2E1 are the primary cytochrome P450 isozymes responsible for the generation of toxic metabolites. Accumulation of NAPQI may occur if primary metabolic pathways are saturated.
INDICATION: – For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.